IL15 and thymic epithelial neoplasm: Finally, pembrolizumab with or without SC-C101 (a superagonist fusion protein of interleukin-15) is currently ongoing as a phase 1/Ib study for 96 patients with pretreated solid tumors, including thymic epithelial tumors (NCT04234113).